Literature DB >> 26498018

Extracardiac-Lodged Mesenchymal Stromal Cells Propel an Inflammatory Response Against Myocardial Infarction via Paracrine Effects.

Yi Peng1, Wei Pan, Yali Ou, Weifang Xu, Sussannah Kaelber, Cesario V Borlongan, Meiqin Sun, Guolong Yu.   

Abstract

Transplantation of stem cells, including mesenchymal stromal cells (MSCs), improves the recovery of cardiac function after myocardial infarction (MI) in experimental studies using animal models and in patients. However, the improvement of cardiac function following MSC transplantation remains suboptimal in both preclinical and clinical studies. Understanding the mechanism of cell therapy may improve its therapeutic outcomes, but the mode of action mediating stem cell promotion of cardiac repair is complex and not fully understood. Recent studies suggest that the immunomodulatory effects of MSCs on the macrophage M1/M2 subtype transition allow the transplanted stem cells to inhibit inflammation-induced injury and promote cardiac repair in acute MI. However, equally compelling evidence shows that there is poor survival and minimal graft persistence of transplanted MSCs within the infarcted heart tissues, negating the view that graft survival per se is required for the observed high rate and long duration of the transition from proinflammatory M1 to reparative M2 macrophages in the infarcted myocardium. Therefore, we raised a novel hypothesis that the therapeutic effects of MSC transplantation for acute MI depends not primarily on the grafted cells in infarct myocardium, but that MSCs migrating to and being lodged in the extracardiac organs, demonstrating good graft survival and persistence, may render the therapeutic effects in MI. More specifically, MSC transplantation promotes the transition from M1 to M2 in extracardiac organs, such as spleen and bone marrow, and therapeutic effects are conferred to the infarcted myocardium via paracrine effects. In MSC transplantation, the conversion from proinflammatory M1 to anti-inflammatory M2 monocytes may occur remotely from the heart and may serve as one of the major pathways in regulating the dual effects of inflammation. This hypothesis, if proven valid, may represent an important new mechanism of action to be considered for the future of MSC transplantation in the treatment of MI.

Entities:  

Mesh:

Year:  2015        PMID: 26498018     DOI: 10.3727/096368915X689758

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  11 in total

1.  Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators.

Authors:  Weiang Yan; Ejlal Abu-El-Rub; Sekaran Saravanan; Lorrie A Kirshenbaum; Rakesh C Arora; Sanjiv Dhingra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 2.  Mesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease.

Authors:  Yueyao Wang; Zhongwen Qi; Zhipeng Yan; Nan Ji; Xiaoya Yang; Dongjie Gao; Leilei Hu; Hao Lv; Junping Zhang; Meng Li
Journal:  Front Cell Dev Biol       Date:  2022-01-12

3.  Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction.

Authors:  Andrew R Kompa; David W Greening; Anne M Kong; Paul J McMillan; Haoyun Fang; Ritika Saxena; Raymond C B Wong; Jarmon G Lees; Priyadharshini Sivakumaran; Andrew E Newcomb; Bakhos A Tannous; Cameron Kos; Lina Mariana; Thomas Loudovaris; Derek J Hausenloy; Shiang Y Lim
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

4.  Human Umbilical Cord Mesenchymal Stem Cells Improve the Necrosis and Osteocyte Apoptosis in Glucocorticoid-Induced Osteonecrosis of the Femoral Head Model through Reducing the Macrophage Polarization.

Authors:  Gang Tian; Chuanjie Liu; Qi Gong; Zhiping Yu; Haitao Wang; Daoqiang Zhang; Haibo Cong
Journal:  Int J Stem Cells       Date:  2022-05-30       Impact factor: 3.011

5.  Persistent Inflammation, Stem Cell-Induced Systemic Anti-Inflammatory Effects, and Need for Repeated Stem Cell Injections: Critical Concepts Influencing Optimal Stem Cell Strategies for Treating Acute Myocardial Infarction and Heart Failure.

Authors:  Stephen E Epstein; Michael J Lipinski; Dror Luger
Journal:  J Am Heart Assoc       Date:  2018-02-13       Impact factor: 5.501

6.  Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.

Authors:  Jun Xu; Yu-Yan Xiong; Qing Li; Meng-Jin Hu; Pei-Sen Huang; Jun-Yan Xu; Xia-Qiu Tian; Chen Jin; Jian-Dong Liu; Li Qian; Yue-Jin Yang
Journal:  Stem Cells Transl Med       Date:  2019-06-27       Impact factor: 6.940

7.  Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization.

Authors:  Ruqin Xu; Fangcheng Zhang; Renjie Chai; Wenyi Zhou; Ming Hu; Bin Liu; Xuke Chen; Mingke Liu; Qiong Xu; Ningning Liu; Shiming Liu
Journal:  J Cell Mol Med       Date:  2019-09-26       Impact factor: 5.310

Review 8.  The involving progress of MSCs based therapy in atherosclerosis.

Authors:  Ying Lin; Wei Zhu; Xiaomin Chen
Journal:  Stem Cell Res Ther       Date:  2020-06-05       Impact factor: 6.832

Review 9.  Mesenchymal Stem Cell-Macrophage Crosstalk and Maintenance of Inflammatory Microenvironment Homeostasis.

Authors:  Di Lu; Yan Xu; Qiuli Liu; Qi Zhang
Journal:  Front Cell Dev Biol       Date:  2021-06-25

10.  Interplay of Autophagy Inducer Rapamycin and Proteasome Inhibitor MG132 in Reduction of Foam Cell Formation and Inflammatory Cytokine Expression.

Authors:  Wei Zhang; Wan Xu; Wenli Chen; Quan Zhou
Journal:  Cell Transplant       Date:  2018-07-12       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.